62 related articles for article (PubMed ID: 20926754)
1. Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure.
Gottlieb SS; Ticho B; Deykin A; Abraham WT; Denofrio D; Russell SD; Chapman D; Smith W; Goldman S; Thomas I
J Clin Pharmacol; 2011 Jun; 51(6):899-907. PubMed ID: 20926754
[TBL] [Abstract][Full Text] [Related]
2. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study.
Greenberg B; Thomas I; Banish D; Goldman S; Havranek E; Massie BM; Zhu Y; Ticho B; Abraham WT
J Am Coll Cardiol; 2007 Aug; 50(7):600-6. PubMed ID: 17692744
[TBL] [Abstract][Full Text] [Related]
3. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
4. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
5. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
6. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
7. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
[TBL] [Abstract][Full Text] [Related]
8. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
[TBL] [Abstract][Full Text] [Related]
9. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
[TBL] [Abstract][Full Text] [Related]
11. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
[TBL] [Abstract][Full Text] [Related]
13. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
14. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
Dickstein K; Gottlieb S; Fleck E; Kostis J; Levine B; DeKock M; LeJemtel T
J Hypertens Suppl; 1994 Jul; 12(2):S31-5. PubMed ID: 7965263
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
